Hungary Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to offer her expert insights into key trends impacting the Hungarian healthcare ecosystem in areas such as in vitro fertilization, market…
Czech Republic Josef Kredba, country manager Czech Republic at G.L. Pharma, an Austrian pharmaceutical company, explains how the company has returned to growth in the challenging Czech generics market and shares his thoughts on market access and pricing conditions for both innovative and generic products. On the one hand, authorities recognize…
Hungary Norbert Langen, founder and CEO of Phytotec, a Hungarian distributor of evidence-based natural Rx and OTC drugs, introduces the company and its unique approach to marketing non-chemically formulated pharmaceuticals in Hungary. Langen describes the importance of clinical evidence and product quality in the company’s portfolio and the advantages that Phytotec…
Hungary Dr Ildikó Horvath, Hungary’s State Secretary for Health explains her role and shares insights on the key health trends in Hungary, the government’s top priority in improving healthcare, the importance of digitalization, and efforts made to close the life expectancy gap with Europe. Hungary is on average five years…
Opinion The AAM’s Chip Davis looks back on 35 years of healthcare system savings from generic pharmaceuticals in the US, and the peril the generics industry faces from the Lower Health Care Costs Act. A key provision of our generic pharmaceutical architecture is in jeopardy. The “180-day exclusivity” is the…
Russia Nadezhda Fedotova and Andrey Zelenin of Lidings law firm gives an update on recent amendments to the labeling legislation for medicines in Russia, their potential impact on the Russian pharmaceutical industry, and the numerous uncertainties still remaining. Despite the time moving up to January 1, 2020, it seems impossible…
Hungary Established in Hungary in 1913, Egis is a traditional Central Eastern European pharmaceutical company with an international footprint across the globe. As one of the four largest historical pharma companies in Hungary, the generic manufacturer now stands as a fully owned subsidiary of the French Servier Group. However, even today…
Hungary Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company’s performance, its exciting new collaboration with Allergan in the US market, and the landmark launch of Gedeon’s first company-developed biosimilar in Japan. Our advancement in biotechnology has been a key development for Gedeon Richter this year…
China Rae Yuan, president of Sinovant Sciences, shares the company’s “transformer” strategy culminating in a strong pipeline of innovative products spanning eight therapeutic areas, and their mission to serve the needs of patients in China and the world. Sinovant Sciences is set up to take an integrated approach to develop…
China Hans Schmid, chairman; and Enrico Magnani, GM, of global cancer supportive care leader Helsinn Pharmaceuticals’ operations in China, share the Swiss company’s strategy in China, having entered in 2012; the milestone of launching their first product in China in November 2018 for chemotherapy-induced nausea and vomiting (CINV); the importance they…
Hungary Irma Veberic, general manager of Roche Hungary, gives her insights on the key issues being faced by the Hungarian healthcare system and the company’s role as a partner in improving health outcomes and raising life expectancy in the country. Veberic goes on to highlight the affiliate’s strong contribution to Hungary…
Opinion Eurasia Group’s Aditya Bhattacharji tackles three more key geopolitical issues that global pharma needs to be cognizant of: the world’s leading drug regulators becoming increasingly strident and active beyond national borders; the impact that greater awareness and work on climate change could have on the industry; and the risks surrounding…
See our Cookie Privacy Policy Here